Blood Podcast Review Series on Follicular Lymphoma
22 snips
Oct 30, 2025 Join Dr. Sarah C. Rutherford, a lymphoma specialist, Dr. Carla Casulo, a clinician-scientist tackling relapsed follicular lymphoma, and Dr. Aaron Perry, a researcher focused on lymphoma biology. They delve into innovative treatment strategies like bispecific antibodies and CAR T-cell therapies. The conversation explores personalizing therapies based on patient history, the biology behind lymphoma transformation, and how emerging tools like ctDNA can guide treatment choices. Plus, they discuss the potential for cures and the complexities of managing high-risk cases.
AI Snips
Chapters
Transcript
Episode notes
Personalize Treatment Decisions
- Tailor therapy to the individual using prior treatments and response duration.
- Consider comorbidities, time since last therapy, and patient preferences when choosing next therapy.
Biology Helps But Isn't Yet Guiding Sequencing
- Tumor biology currently has limited predictive use in routine sequencing decisions.
- Specific mutations like EZH2 help, but broader biology-driven guidance is not yet standard.
Frontline Trials Moving Toward Bispecifics
- Many frontline trials now test bispecific antibodies, often combined with lenalidomide or other agents.
- These approaches aim to replace chemotherapy with potentially better tolerated immune therapies.